Rapid Dose Therapeutics Corp. (RDTCF)
- Newsfile
Rapid Dose Therapeutics Commits to NFL-Funded Clinical Trial Application
Burlington, Ontario--(Newsfile Corp. - May 29, 2024) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company") announces its collaboration in the National Football League (NFL) – funded clinical trial program entitled "Naturally Produced Cannabinoids for Pain Management and Neuroprotection from Concussion and Participation in Contact Sports" led by Dr. J. Patrick Neary and researchers at the University of Regina. RDT will partake in a randomized, two-arm clinical study, which is part
- Newsfile
Rapid Dose Therapeutics and McMaster University's Incorporation of Loratadine-Cyclodextrin Complexes in Oral Thin Films for Rapid Drug Delivery
Burlington, Ontario--(Newsfile Corp. - May 22, 2024) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company") trading on the Canadian Securities Exchange ("CSE") under the symbol DOSE in partnership with McMaster University ("McMaster") is pleased to announce the publication of the results of their collaborative research project titled "Incorporation of Loratadine-Cyclodextrin Complexes in Oral Thin Films ("OTF") for Rapid Drug Delivery" in the Journal of Pharmaceutical Sciences.This
- Business Wire
Rapid Dose Therapeutics Reports Fiscal Year 2023 Financial Results
BURLINGTON, Ontario, June 28, 2023--Rapid Dose Therapeutics Corp. ("RDT" or the "Company") (CSE: DOSE), today reported its financial results for the year ended February 28, 2023.
